ITMI20010009A1 - Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera - Google Patents
Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera Download PDFInfo
- Publication number
- ITMI20010009A1 ITMI20010009A1 IT2001MI000009A ITMI20010009A ITMI20010009A1 IT MI20010009 A1 ITMI20010009 A1 IT MI20010009A1 IT 2001MI000009 A IT2001MI000009 A IT 2001MI000009A IT MI20010009 A ITMI20010009 A IT MI20010009A IT MI20010009 A1 ITMI20010009 A1 IT MI20010009A1
- Authority
- IT
- Italy
- Prior art keywords
- brivudine
- treatment
- patients
- magnesium stearate
- aciclovir
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 title 1
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 claims description 67
- 229960001169 brivudine Drugs 0.000 claims description 63
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 9
- 235000019359 magnesium stearate Nutrition 0.000 claims 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims 9
- 239000008213 purified water Substances 0.000 claims 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229910002012 Aerosil® Inorganic materials 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 229920001531 copovidone Polymers 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- 229920002261 Corn starch Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 38
- 229960004150 aciclovir Drugs 0.000 description 34
- 208000007514 Herpes zoster Diseases 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 229960004396 famciclovir Drugs 0.000 description 4
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 231100000046 skin rash Toxicity 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940093257 valacyclovir Drugs 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000009A ITMI20010009A1 (it) | 2001-01-03 | 2001-01-03 | Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera |
| IE20010413A IE20010413A1 (en) | 2001-01-03 | 2001-04-25 | Once-a-day pharmaceutical composition containing Brivudine |
| GB0110682A GB2370771A (en) | 2001-01-03 | 2001-05-01 | Once-a-day pharmaceutical composition comprising brivudine |
| HR20010345A HRPK20010345B3 (en) | 2001-01-03 | 2001-05-11 | Pharmaceutical preparation containing brivudin to be administered once a day |
| CH00987/01A CH695662A5 (de) | 2001-01-03 | 2001-05-29 | Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichungn. |
| SE0102309A SE0102309L (sv) | 2001-01-03 | 2001-06-28 | Farmaceutisk engång-om-dagen-komposition innehållande brivudin |
| DKPA200101019A DK177084B1 (da) | 2001-01-03 | 2001-06-29 | Farmaceutisk præparat indeholdende brivudin til indgivelse én gang dagligt |
| FR0108596A FR2818907B1 (fr) | 2001-01-03 | 2001-06-29 | Utilisation de la brivudine pour la preparation d'une composition pharmaceutique |
| NL1018431A NL1018431C2 (nl) | 2001-01-03 | 2001-07-02 | EÚnmaal daags farmaceutische samenstelling die brivudine bevat. |
| FI20011446A FI20011446A (fi) | 2001-01-03 | 2001-07-03 | Farmaseuttinen, brivudiinia sisältävä, kerran päivässä käytettävä koostumus |
| BE2001/0452A BE1014522A5 (fr) | 2001-01-03 | 2001-07-04 | Composition pharmaceutique et son utilisation. |
| UA2001074658A UA76402C2 (en) | 2001-01-03 | 2001-07-04 | Use of brivudine in acute herpes zoster infections and post-herpetic neuralgia |
| SK957-2001A SK287043B6 (sk) | 2001-01-03 | 2001-07-04 | Použitie brivudínu na liečenie infekcií herpes alebo post-herpetickej neuralgie |
| CZ20012464A CZ20012464A3 (cs) | 2001-01-03 | 2001-07-04 | Farmaceutický prostředek |
| HU0102816A HUP0102816A3 (en) | 2001-01-03 | 2001-07-05 | Pharmaceutical composition containg brivudine |
| ES200101566A ES2192456B1 (es) | 2001-01-03 | 2001-07-05 | Composicion farmaceutica de una vez al dia que contiene brivudina. |
| PT102642A PT102642B (pt) | 2001-01-03 | 2001-07-05 | Composicao farmaceutica de dosagem unica diaria contendo brivudine |
| PL01348480A PL348480A1 (en) | 2001-01-03 | 2001-07-05 | Brivudine containing pharmacological compositions to be administered once a day |
| GR20010100322A GR1004012B (el) | 2001-01-03 | 2001-07-05 | Απαξ ημερησιως χορηγουμενη φαρμακευτικη συνθεση που εμπεριεχει βριβουδινη |
| AT0805702U AT6141U1 (de) | 2001-01-03 | 2002-07-03 | Brivudin enthaltende pharmazeutische zusammensetzung für die einmal tägliche verabreichung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000009A ITMI20010009A1 (it) | 2001-01-03 | 2001-01-03 | Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITMI20010009A0 ITMI20010009A0 (it) | 2001-01-03 |
| ITMI20010009A1 true ITMI20010009A1 (it) | 2002-07-03 |
Family
ID=11446384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT2001MI000009A ITMI20010009A1 (it) | 2001-01-03 | 2001-01-03 | Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera |
Country Status (20)
| Country | Link |
|---|---|
| AT (1) | AT6141U1 (fi) |
| BE (1) | BE1014522A5 (fi) |
| CH (1) | CH695662A5 (fi) |
| CZ (1) | CZ20012464A3 (fi) |
| DK (1) | DK177084B1 (fi) |
| ES (1) | ES2192456B1 (fi) |
| FI (1) | FI20011446A (fi) |
| FR (1) | FR2818907B1 (fi) |
| GB (1) | GB2370771A (fi) |
| GR (1) | GR1004012B (fi) |
| HR (1) | HRPK20010345B3 (fi) |
| HU (1) | HUP0102816A3 (fi) |
| IE (1) | IE20010413A1 (fi) |
| IT (1) | ITMI20010009A1 (fi) |
| NL (1) | NL1018431C2 (fi) |
| PL (1) | PL348480A1 (fi) |
| PT (1) | PT102642B (fi) |
| SE (1) | SE0102309L (fi) |
| SK (1) | SK287043B6 (fi) |
| UA (1) | UA76402C2 (fi) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239527B1 (es) * | 2004-03-01 | 2006-11-16 | M. Cruz Fernandez Gonzalez | Composicion farmacologica de uso topico para el tratamiento del herpes zoster. |
| CN113712928A (zh) * | 2021-09-29 | 2021-11-30 | 重庆市力扬医药开发有限公司 | 经口腔粘膜吸收的溴夫定药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0104857A1 (en) * | 1982-09-28 | 1984-04-04 | Beecham Group Plc | Deoxyuridine compounds, methods for preparing them and their use in medicine |
| IT1170232B (it) * | 1983-10-31 | 1987-06-03 | Anna Gioia Stendardi | Composizioni terapeutiche ad attivita' antivirale |
| US5446031A (en) * | 1991-04-24 | 1995-08-29 | Yamasa Shuyu Kabushiki Kaisha | 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives |
| PT874631E (pt) * | 1996-01-19 | 2004-04-30 | Glaxo Group Ltd | Utilizacao de valaciclovir para a manufactura de um medicamento para o tratamento de herpes genital por aplicacao diaria unica |
-
2001
- 2001-01-03 IT IT2001MI000009A patent/ITMI20010009A1/it unknown
- 2001-04-25 IE IE20010413A patent/IE20010413A1/en not_active IP Right Cessation
- 2001-05-01 GB GB0110682A patent/GB2370771A/en not_active Withdrawn
- 2001-05-11 HR HR20010345A patent/HRPK20010345B3/xx not_active IP Right Cessation
- 2001-05-29 CH CH00987/01A patent/CH695662A5/de not_active IP Right Cessation
- 2001-06-28 SE SE0102309A patent/SE0102309L/ not_active Application Discontinuation
- 2001-06-29 FR FR0108596A patent/FR2818907B1/fr not_active Expired - Lifetime
- 2001-06-29 DK DKPA200101019A patent/DK177084B1/da not_active IP Right Cessation
- 2001-07-02 NL NL1018431A patent/NL1018431C2/nl not_active IP Right Cessation
- 2001-07-03 FI FI20011446A patent/FI20011446A/fi not_active Application Discontinuation
- 2001-07-04 BE BE2001/0452A patent/BE1014522A5/fr not_active IP Right Cessation
- 2001-07-04 UA UA2001074658A patent/UA76402C2/uk unknown
- 2001-07-04 CZ CZ20012464A patent/CZ20012464A3/cs unknown
- 2001-07-04 SK SK957-2001A patent/SK287043B6/sk not_active IP Right Cessation
- 2001-07-05 PL PL01348480A patent/PL348480A1/xx not_active Application Discontinuation
- 2001-07-05 PT PT102642A patent/PT102642B/pt active IP Right Grant
- 2001-07-05 GR GR20010100322A patent/GR1004012B/el unknown
- 2001-07-05 ES ES200101566A patent/ES2192456B1/es not_active Expired - Fee Related
- 2001-07-05 HU HU0102816A patent/HUP0102816A3/hu unknown
-
2002
- 2002-07-03 AT AT0805702U patent/AT6141U1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH695662A5 (de) | 2006-07-31 |
| FR2818907B1 (fr) | 2006-05-26 |
| GB0110682D0 (en) | 2001-06-20 |
| HUP0102816A2 (en) | 2002-10-28 |
| NL1018431C2 (nl) | 2002-07-05 |
| IE20010413A1 (en) | 2003-04-16 |
| GR1004012B (el) | 2002-11-01 |
| FI20011446A0 (fi) | 2001-07-03 |
| ES2192456A1 (es) | 2003-10-01 |
| ITMI20010009A0 (it) | 2001-01-03 |
| SE0102309D0 (sv) | 2001-06-28 |
| GR20010100322A (el) | 2002-10-08 |
| AT6141U1 (de) | 2003-05-26 |
| SE0102309L (sv) | 2002-07-04 |
| PT102642A (pt) | 2002-07-31 |
| GB2370771A (en) | 2002-07-10 |
| HRPK20010345B3 (en) | 2005-02-28 |
| UA76402C2 (en) | 2006-08-15 |
| DK200101019A (da) | 2002-07-04 |
| PT102642B (pt) | 2003-06-30 |
| PL348480A1 (en) | 2002-07-15 |
| CZ20012464A3 (cs) | 2002-08-14 |
| HRP20010345A2 (en) | 2003-08-31 |
| SK287043B6 (sk) | 2009-10-07 |
| HU0102816D0 (en) | 2001-09-28 |
| FR2818907A1 (fr) | 2002-07-05 |
| ES2192456B1 (es) | 2005-02-01 |
| DK177084B1 (da) | 2011-07-11 |
| BE1014522A5 (fr) | 2003-12-02 |
| SK9572001A3 (en) | 2003-03-04 |
| FI20011446A (fi) | 2002-07-04 |
| HUP0102816A3 (en) | 2005-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013336491B2 (en) | Pharmaceutical antiretroviral composition | |
| CA2633603A1 (en) | Pharmaceutical combination | |
| WO2014184553A1 (en) | Pharmaceutical antiretroviral compositions | |
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| IT9021833A1 (it) | Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids. | |
| US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
| US20140193491A1 (en) | Pharmaceutical antiretroviral composition | |
| JP2022550828A (ja) | カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法 | |
| ITMI20010009A1 (it) | Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera | |
| CA2782779C (en) | Mucoadhesive buccal tablets for the treatment of orofacial herpes | |
| JP2009507850A5 (fi) | ||
| RU2008108216A (ru) | Фармацевтические дозированные формы и составы, содержащие лекозотан | |
| WO2015014737A1 (en) | Multilayer tablet formulations comprising tenofovir and entecavir | |
| TR2021018192A1 (tr) | Anti̇-vi̇ral etki̇ gösterebi̇lecek yeni̇ i̇laç formülasyonlarinin hazirlanmasi ve covi̇d-19?a karşi etki̇si̇ni̇n araştirilmasi | |
| Zhang et al. | Clinical pharmacology of the unboosted HIV integrase strand transfer inhibitor (INSTI) bictegravir (BIC) | |
| Ekmekyapar et al. | Antiviral Drugs and Their Toxicities | |
| CN105434364B (zh) | 一种托匹司他缓释颗粒及其制备方法 | |
| WO2022118020A1 (en) | Method of treating viral infection | |
| WO2021057661A1 (zh) | 一种降糖药物组合物 | |
| SI20854A (sl) | Farmacevtska zmes z učinkovino Brivudine z enkratnim dnevnim doziranjem | |
| Sabo et al. | Lack of a pharmacokinetic effect between steady-state tipranavir/ritonavir (TPV/r) and single-dose valacyclovir in healthy volunteers | |
| EA005497B1 (ru) | Применение фармацевтической композиции, содержащей бривудин, для лечения герпесвирусных инфекций | |
| RO121585B1 (ro) | Utilizarea brivudinei în tratamentul infectiilor de tip herpes zoster sau nevralgiei post-herpetice | |
| IL26469A (en) | Synergistic pharmaceutical composition containing sulphamethopyrazine and pyrimethamine having antimalarial action |